Progress in the evaluation of CDK inhibitors as anti-tumor agents.

[1]  James R Bischoff,et al.  CDK inhibitors in cancer therapy: what is next? , 2008, Trends in pharmacological sciences.

[2]  Patricia M. LoRusso,et al.  A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors , 2008, Investigational New Drugs.

[3]  Thomas S. Lin,et al.  Flavopiridol in the treatment of chronic lymphocytic leukemia , 2007, Current opinion in oncology.

[4]  Pierre Dubus,et al.  Cdk1 is sufficient to drive the mammalian cell cycle , 2007, Nature.

[5]  M. Valentine,et al.  CDK11p58 is required for the maintenance of sister chromatid cohesion , 2007, Journal of Cell Science.

[6]  A. Tward,et al.  Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC , 2007, Nature Medicine.

[7]  L. Vassilev,et al.  Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[8]  Thomas S. Lin,et al.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.

[9]  P. Workman,et al.  A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days , 2006, British Journal of Cancer.

[10]  P. Fischer,et al.  REPLACE: A Strategy for Iterative Design of Cyclin‐Binding Groove Inhibitors , 2006, Chembiochem : a European journal of chemical biology.

[11]  E. Pérez-Payá,et al.  Identification of an Hexapeptide That Binds to a Surface Pocket in Cyclin A and Inhibits the Catalytic Activity of the Complex Cyclin-dependent Kinase 2-Cyclin A* , 2006, Journal of Biological Chemistry.

[12]  L. Vassilev,et al.  Cell Cycle Synchronization at the G2/M Phase Border by Reversible Inhibition of CDK1 , 2006, Cell cycle.

[13]  A. Calcagno,et al.  Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor , 2006, Molecular Cancer Therapeutics.

[14]  E. Eisenhauer,et al.  A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma , 2006, Sarcoma.

[15]  P. Nowell,et al.  Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. , 2006, Blood.

[16]  S. Ely,et al.  A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. , 2006, Cancer research.

[17]  S. Emanuel,et al.  Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. , 2006, Bioorganic & medicinal chemistry letters.

[18]  Hongmao Sun,et al.  Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Yan Geng,et al.  Requirement for CDK4 kinase function in breast cancer. , 2006, Cancer cell.

[21]  Tiansen Li,et al.  Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. , 2006, Cancer cell.

[22]  M. Barbacid,et al.  Mammalian cyclin-dependent kinases. , 2005, Trends in biochemical sciences.

[23]  S. Emanuel,et al.  The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. , 2005, Cancer research.

[24]  P. Loyer,et al.  Role of CDK/cyclin complexes in transcription and RNA splicing. , 2005, Cellular signalling.

[25]  Hiroshi Yasui,et al.  Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. , 2005, Blood.

[26]  D. Lane,et al.  Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. , 2005, Cancer research.

[27]  Peter M Fischer,et al.  Recent progress in the discovery and development of cyclin-dependent kinase inhibitors , 2005, Expert opinion on investigational drugs.

[28]  D. W. Fry,et al.  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.

[29]  S. Dakhil,et al.  A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109 , 2005, Cancer Chemotherapy and Pharmacology.

[30]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[31]  P. Fischer,et al.  Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. , 2004, Organic & biomolecular chemistry.

[32]  Pierre Dubus,et al.  Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6 , 2004, Cell.

[33]  M. Blagosklonny,et al.  Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor , 2004, Cancer Research.

[34]  Punit Marathe,et al.  N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. , 2004, Journal of medicinal chemistry.

[35]  P. Kantoff,et al.  A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer , 2004, Clinical Cancer Research.

[36]  K. Shokat,et al.  Targets of the cyclin-dependent kinase Cdk1 , 2003, Nature.

[37]  P. Kaldis,et al.  Cdk2 Knockout Mice Are Viable , 2003, Current Biology.

[38]  Pierre Dubus,et al.  Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice , 2003, Nature Genetics.

[39]  E. Vokes,et al.  Phase II study of flavopiridol in patients with advanced colorectal cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Ricardo M Biondi,et al.  Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. , 2003, The Biochemical journal.

[41]  H. Koeppen,et al.  Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. , 2003, Cancer research.

[42]  M. Okuda.  The role of nucleophosmin in centrosome duplication , 2002, Oncogene.

[43]  G Vogel,et al.  Cycling Toward Stockholm , 2001, Science.

[44]  J. Qin,et al.  Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. , 2000, Genes & development.

[45]  Michele Pagano,et al.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 , 1999, Nature Cell Biology.

[46]  W. Kaelin,et al.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Meites,et al.  Nobel prize in physiology or medicine. , 1978, Science.